Publications by authors named "Xavier Murraciole"

Article Synopsis
  • Pediatric cancers are rare, accounting for about 2,500 new cases annually in France, and a national web-based conference has been established to discuss treatment options for these patients requiring radiotherapy.
  • From 2012 to 2018, over 1,000 cases were discussed during 142 meetings, with a mean patient age of 10 years and an average of 6 attendees per meeting.
  • Ultimately, the conference led to modifications in radiation protocols in 15% of cases, highlighting the importance of collaboration in managing these complex and rare pediatric cancers to enhance treatment quality.
View Article and Find Full Text PDF

Purpose: To explore patient and nurse satisfaction, compliance with best practice, technical feasibility and safety of home infusion of a bisphosphonate.

Methods: Prospective 1-year survey of home zoledronic acid therapy (4 mg, 15-min intravenous, every three to four weeks) in patients with bone metastases secondary to a solid malignancy. A physician questionnaire, nurse satisfaction/feasibility questionnaire and patient satisfaction questionnaire were administered.

View Article and Find Full Text PDF

Purpose: This study aimed to explore patient and nurse satisfaction, compliance with best practice, technical feasibility and safety of home infusion of the bisphosphonate zoledronic acid (ZOL).

Methods: This was a prospective 1-year survey of home ZOL therapy (4 mg Zometa, 15-min i.v.

View Article and Find Full Text PDF

Recent studies suggest the possibility of a direct antiangiogenic effect of anti-epidermal growth factor receptor (EGFR) drugs due to the presence of EGFR on endothelial cells. The aim of this study was to analyze the direct effect on endothelial cells of associating EGFR targeting, vascular endothelial growth factor receptor (VEGFR)-2 targeting, and irradiation. We examined both the cytotoxic effects and the effect on molecular markers resulting from the combined action of gefitinib (Iressa; anti-EGFR), ZM317450 [VEGFR tyrosine kinase inhibitor (VTKI); anti-VEGFR-2], and irradiation (radiation therapy) on HMME7 cells, an immortalized microvascular endothelial cell of human origin.

View Article and Find Full Text PDF